NCT04128709 Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use
| NCT ID | NCT04128709 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Christopher Cooper |
| Condition | Urinary Bladder, Neurogenic |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2019-11-19 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2019-11-19 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators have developed a novel pressure monitoring device that hooks to standard urinary catheters that are used by patients with a neurogenic bladder on daily clean intermittent catheterization. The device has already been demonstrated to be accurate compared to the gold standard in clinic urodynamics. This study will assess the patients and care givers ability and experience using the device in a home setting.
Eligibility Criteria
Inclusion Criteria: * must have diagnosed neurogenic bladder Exclusion Criteria: * None
Contact & Investigator
Christopher S Cooper, MD
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT04128709 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 99 Years, studying Urinary Bladder, Neurogenic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04128709 currently recruiting?
Yes, NCT04128709 is actively recruiting participants. Contact the research team at christopher-cooper@uiowa.edu for enrollment information.
Where is the NCT04128709 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT04128709 clinical trial?
NCT04128709 is sponsored by Christopher Cooper. The principal investigator is Christopher S Cooper, MD at University of Iowa. The trial plans to enroll 50 participants.